<DOC>
	<DOCNO>NCT00423969</DOCNO>
	<brief_summary>The purpose study investigate whether addition galantamine commonly use antidepressant , escitalopram ( Lexapro ) , useful treatment memory think problem frequently see depression . At present , galantamine approve use treatment Alzheimer ’ disease dementia , use treatment depression young patient . Possible genetic effect depress individual also study . This study involve collect blood patient depression . DNA , genetic material cell , obtain blood sample . The DNA study determine contribution different gene development depression . These blood sample extremely useful researcher try determine genetic risk factor may lead depression .</brief_summary>
	<brief_title>Galantamine Augmentation Escitalopram Treatment Depression</brief_title>
	<detailed_description>HYPOTHESES/OBJECTIVES Aim 1 : To investigate whether patient treat escitalopram combination galantamine show significantly great improvement depression compare patient treated escitalopram alone . H1 : Patients treat escitalopram galantamine combination significantly great improvement Hamilton Depression Rating Scale ( HDRS ) Clinical Global Improvement ( CGI ) scale compare patient treat escitalopram placebo . Aim 2 : To investigate whether treatment escitalopram combination galantamine lead great improvement cognitive function depress patient compare escitalopram alone . H2 : Patients treat escitalopram galantamine combination significantly great improvement score Selective Reminding Test ( SRT ) Trail Making Test ( TMT ) patient treat escitalopram placebo . Study Design Method : This randomize , single blind , parallel-group , placebo control study total 20 subject , 10 arm : one arm would escitalopram + galantamine treatment arm escitalopram + placebo treatment . The subject blind galantamine placebo , unblinded escitalopram . The total duration study 10 week . After baseline visit , patient complete 8 week study medication .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<criteria>1 . Age 18 – 60 year age inclusive 2 . Satisfy DSMIVTR criterion Major Depression 3 . RAVLT score decrease normative mean age 4 . 17 item HDRS rating &gt; 18 5 . Give informed consent approve local IRB 6 . On antidepressant want tapered current antidepressant medication due side effect inefficacy ; 7 . Not monoamine oxidase inhibitor ( MAOIs ) 3 week start study . 1 . Comorbid psychotic disorder schizophrenia schizoaffective disorder 2 . Significant suicidal homicidal risk 3 . Clinically significant medical illness 4 . Allergy intolerance escitalopram galantamine 5 . Woman child bear age ( except surgically sterile tubal ligation ) 6 . Satisfy criterion substance dependence within 6 month prior start study 7 . History intolerance escitalopram galantamine ; 8 . On medication significant adverse interaction either escitalopram galantamine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Depression</keyword>
	<keyword>Cognitive Impairment</keyword>
</DOC>